HbA1c screening in patients with early breast cancer receiving endocrine therapy
Adherence to HbA1c screening may be affected if the test is an extra step for patients. Targeted HbA1c screening may be beneficial for patients with early breast cancer with overweight or older age receiving endocrine therapy. Further research is needed to improve implementation and participation.
Authors
- Signe Borgquist (ORCID: https://orcid.org/0000-0001-7938-8893)
- Tinne Laurberg (ORCID: https://orcid.org/0000-0002-7555-2665)
- Jonas Busk Holm (ORCID: https://orcid.org/0009-0009-6004-0104)
- Sine Skovbjerg (ORCID: https://orcid.org/0000-0003-0616-3137)
- Loes H.C. Nissen (ORCID: https://orcid.org/0009-0005-5276-7195)
- Morten Charles (ORCID: https://orcid.org/0000-0003-0327-9564)
- Ole L. Dollerup (ORCID: https://orcid.org/0000-0001-6924-7114)
Institutions
- Steno Diabetes Centers (DK)
- Aarhus University (DK)
- Aarhus University Hospital (DK)
Publication Details
- Journal
- Endocrine Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1530/eo-25-0058
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00